Research & Development

17 Mar 2020
- Drug Discovery
- Research & Development
AcelRx Pharmaceuticals to acquire Tetraphase Pharmaceuticals

By PBR Staff Writer

AcelRx Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced the execution of a definitive merger agreement to acquire Tetraphase Pharmaceuticals, Inc. (Tetraphase) in a stock for stock deal at an exchange ratio of 0.6303 shares of AcelRx for each share of Tetraphase, or approximately $14.4 million as of the close of trading on March 13, 2020, plus a contingent value right (CVR).
16 Mar 2020
Drug Discovery
Research & Development
BioStem Life Sciences announces expansion; contract manufacturing capabilities, and research and development laboratory

By PBR Staff Writer

BioStem Life Sciences, a wholly owned subsidiary of BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company") a leading life sciences company specializing in perinatal tissue-based allografts for use in regenerative therapies, today announced the buildout of a brand new R&D lab.
16 Mar 2020
Drug Discovery
Research & Development
Can-Fite to explore the anti-coronavirus effects of piclidenoson in collaboration with Lewis Katz School of Medicine at Temple University

By PBR Staff Writer

Can-Fite BioPharma, a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, is entering into a collaborative research agreement with the Lewis Katz School of Medicine at Temple University, Philadelphia, USA.
12 Mar 2020
Drug Discovery
Research & Development
Forty Seven, Rocket collaborate on new treatment for Fanconi Anemia

By PBR Staff Writer

Forty Seven and Rocket Pharmaceuticals have entered into a research collaboration for evaluating a new treatment regimen in Fanconi Anemia, a rare paediatric disease.
12 Mar 2020
Drug Discovery
Research & Development
Silverback Therapeutics raises $78.5m in oversubscribed Series B financing

By PBR Staff Writer

Silverback Therapeutics (“Silverback”) (“the Company”), a private biopharmaceutical company pioneering a new class of immune-modulating ImmunoTAC drug conjugates targeting previously inaccessible disease pathways, today announced the close of an oversubscribed $78.5 million Series B financing round.
12 Mar 2020
Drug Discovery
Research & Development
Brii Biosciences provides funding to Columbia University for research on COVID-19 and other coronaviruses

By PBR Staff Writer

Brii Biosciences (“Brii Bio”) and Columbia University have entered into a memorandum of understanding through which Brii Bio will provide funding to support research to be conducted by investigators at the university and led by David Ho, M.D., founding scientific director of the Aaron Diamond AIDS Research Center and professor of medicine at the Vagelos College of Physicians and Surgeons.
11 Mar 2020
Drug Discovery
Research & Development
Kuur Therapeutics launches to develop and commercialise off-the-shelf CAR-NKT cell therapies

By PBR Staff Writer

Kuur Therapeutics announced the launch of its new business in partnership with Baylor College of Medicine and Baylor’s Center for Cell and Gene Therapy. Houston-based Kuur Therapeutics will advance the work of its predecessor, Cell Medica, to develop anti-cancer therapies using its innovative chimeric antigen receptor natural killer T cell (CAR-NKT) therapy platform.
09 Mar 2020
Drug Discovery
Research & Development
Mount Sinai and Harbour BioMed collaborate to advance novel biotherapies to treat cancer and coronavirus COVID-19

By PBR Staff Writer

Mount Sinai Health System and Harbour BioMed (HBM) have entered into a multi-year, multifaceted collaboration to develop novel, fully human antibodies for the treatment and prevention of various diseases including oncology and immunology.
05 Mar 2020
Drug Discovery
Research & Development
Amunix raises $73m in Series A financing led by Omega Funds

By PBR Staff Writer

Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the successful completion of an oversubscribed $73 million Series A financing.
05 Mar 2020
Drug Discovery
Research & Development
Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research discover novel class of candidate anti malaria agents

By PBR Staff Writer

Merck, known as MSD outside the United States and Canada, and the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, today announced the publication of research on the discovery of a novel class of candidate antimalarial agents that block multiple stages of the lifecycle of the parasite that causes the disease.

Drug Discovery

Research & Development

OZMOSI and Planview partner to enhance pharmaceutical data integration

Cumberland to sell drug portfolio to Apotex for $100m

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Viatris files applications in Japan for approval of Effexor to treat GAD

Scholar Rock submits application of SMA therapy to FDA

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Gerresheimer at CPHI Frankfurt 2025

Gerresheimer

Suppliers

No data found

Research & Development

AcelRx Pharmaceuticals to acquire Tetraphase Pharmaceuticals

BioStem Life Sciences announces expansion; contract manufacturing capabilities, and research and development laboratory

Can-Fite to explore the anti-coronavirus effects of piclidenoson in collaboration with Lewis Katz School of Medicine at Temple University

Forty Seven, Rocket collaborate on new treatment for Fanconi Anemia

Silverback Therapeutics raises $78.5m in oversubscribed Series B financing

Brii Biosciences provides funding to Columbia University for research on COVID-19 and other coronaviruses

Kuur Therapeutics launches to develop and commercialise off-the-shelf CAR-NKT cell therapies

Mount Sinai and Harbour BioMed collaborate to advance novel biotherapies to treat cancer and coronavirus COVID-19

Amunix raises $73m in Series A financing led by Omega Funds

Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research discover novel class of candidate anti malaria agents

Pharmaceutical Business review is using cookies

Research & Development

Patient Enrollment

Drug Filing

Manufacturing

Packaging

No data found